The REWIND Trial Showed Weekly Dulaglutide Reduces Cardiovascular Events in Men with T2DM. Here Is the Evidence.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Marcus is 54 years old, a regional sales director for a manufacturing firm based in central Illinois. He drives 400 miles a week, eats lunch from a gas station at least three days out of five, and owns a Friday routine the way a priest owns a liturgy: coffee at 6 a.m., conference call at 7, injection in the company parking lot at 8, on the road by 8:15. The injection is Trulicity. He’s been on it for two years. He picked Friday because it was the day he remembered to do it, the end of the workweek, the beginning of something like rest.

Marcus came to see me not because his endocrinologist sent him, but because his father died at 57 from a heart attack, and Marcus had just turned 53 and the number felt close. His A1c when he walked in was 7.4 percent. His LDL was 92. His ApoB was 118. His blood pressure ran 138/86. His CAC score, which no one had ever ordered for him, came back at 240, the top quartile for a man his age, a number that changes conversations.

He asked me one question: “Is this medication helping my heart, or is it just helping my blood sugar?”

That question is worth 10,000 words. Because the answer is not simple, but it is specific. Trulicity, the brand name for dulaglutide, is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes. It is not approved for weight management. It does not produce the weight loss numbers that semaglutide or tirzepatide produce. What it does, and what the REWIND trial documented with precision, is reduce major adverse cardiovascular events in a patient population that included men like Marcus: not just people with established cardiovascular disease, but people with cardiovascular risk factors who had not yet had their first event.

That distinction matters. Most GLP-1 CVOT trials enrolled patients with established cardiovascular disease. REWIND enrolled 31.5 percent of its participants at primary prevention status, patients with cardiovascular risk factors but no prior heart attack or stroke. That was not an accident. It was a design choice that makes the REWIND data applicable to a broader population of men sitting in parking lots on Friday mornings, injecting medication they understand only partially.

Marcus wanted to understand it fully. This article is the answer I gave him.

Methodology Note

This article draws from the FDA-approved prescribing information for dulaglutide (NDA 125469, most recent label revision 2023), the published RCT corpus listed in the References section, and real-world evidence from Optum Labs Data Warehouse, the TriNetX Global Collaborative Network, and peer-reviewed publications in NEJM, JAMA, Lancet, Circulation, JACC, Diabetes Care, and Nature Medicine. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article. Compound pharmacies, off-label dosing regimens, and unapproved formulations are not endorsed.

What Trulicity Is, FDA Approval Status and Indication

Generic name: Dulaglutide Brand name: Trulicity Manufacturer: Eli Lilly and Company NDA number: 125469 Original FDA approval date: September 18, 2014 Drug class: Glucagon-like peptide-1 (GLP-1) receptor agonist; incretin mimetic

FDA-Approved Indication

From the USPI Section 1, Indications and Usage:

“Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.”

That second clause, cardiovascular risk reduction, was added to the label in May 2020 following the REWIND trial results. It is the most clinically significant update to the Trulicity label since approval, and it is the reason this article exists within men series.

Approved Dose Range

• 0.75 mg subcutaneous injection once weekly (starting dose)
• 1.5 mg subcutaneous injection once weekly (maintenance dose, most common)
• 3.0 mg once weekly (uptitration option added 2020)
• 4.5 mg once weekly (maximum dose, added 2020)

Uptitration from 0.75 mg to 1.5 mg typically occurs after 4 weeks. Further uptitration to 3.0 mg and 4.5 mg may occur at 4-week intervals for additional glycemic control. The single-dose pen delivers the full dose automatically; the patient does not see or manipulate the needle.

Route of Administration and Formulation

Subcutaneous injection, once weekly. Available as a single-dose, single-use autoinjector pen (0.5 mL injection). The pen device does not require reconstitution, refrigeration after initial opening for the injection period, or visible needle handling. The patient presses the pen against the abdomen, outer thigh, or upper arm and activates the injection with a click. Total injection time is approximately 5 seconds.

Black-Box Warning (Verbatim from USPI)

“WARNING: RISK OF THYROID C-CELL TUMORS

In male and female rats, dulaglutide causes a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether dulaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.

Trulicity is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with the use of Trulicity and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).”

This warning is class-wide across all GLP-1 receptor agonists. The rodent data is real. The human relevance remains undetermined as of this writing. In 15 years of GLP-1 RA clinical use and post-marketing surveillance, medullary thyroid cancer has not emerged as a confirmed population-level risk in humans. But the contraindication stands, and patients with a personal or family history of MTC or MEN-2 should not take this class of medication.

What Trulicity Is NOT Approved For

Trulicity is not approved for:

• Weight management or chronic weight management (that indication belongs to Saxenda and Wegovy in the liraglutide and semaglutide class, respectively)
• Type 1 diabetes mellitus
• Diabetic ketoacidosis
• Patients with prior serious hypersensitivity reactions to dulaglutide

The average weight loss on Trulicity in the AWARD and REWIND trials was 1.5 to 3.0 kg over 26 to 52 weeks, a modest glycemic-era weight reduction, not a weight-management signal. Men who come to clinic expecting Ozempic-level weight loss from Trulicity need a calibrated expectation.

The Mechanism, How It Works

GLP-1 Receptor Agonism: From Gut to Heart

Dulaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a peptide hormone produced by L-cells in the small intestinal mucosa in response to nutrient ingestion. It shares approximately 90 percent amino acid sequence homology with endogenous GLP-1, modified to resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and to extend the circulating half-life to approximately 5 days via its IgG4 Fc fusion structure, long enough to support once-weekly dosing.

When dulaglutide binds the GLP-1 receptor, it activates a G-protein-coupled intracellular signaling cascade that produces several simultaneous effects:

Pancreatic effects (glucose-dependent): Dulaglutide stimulates insulin secretion from beta cells only in the presence of high glucose. This glucose-dependency is why monotherapy with a GLP-1 RA carries minimal hypoglycemia risk, the drug does not force insulin release when glucose is already low. It also suppresses glucagon secretion from pancreatic alpha cells, reducing post-prandial hepatic glucose output.

Gastric effects: GLP-1 receptor activation slows gastric emptying, reducing the rate at which glucose enters the circulation after meals. This smooths post-prandial glucose spikes and contributes to early satiety, the mechanism behind modest weight reduction in T2DM patients.

Central nervous system effects: GLP-1 receptors are expressed in the hypothalamus, brainstem, and reward circuitry. Central receptor activation reduces appetite and food intake. The CNS signal is less potent with dulaglutide than with high-dose semaglutide, which accounts for the difference in weight-loss magnitude between these agents 5 / Solid 30412-6).

The Cardiac Mechanism: Direct and Indirect

The cardiac question has two parts: what does weight loss do for the heart, and does dulaglutide do something for the heart beyond weight loss?

Weight-mediated cardiac benefit: Even modest weight reduction of 3 to 5 percent body weight produces measurable reductions in systolic blood pressure, triglycerides, and CRP, each an independent cardiac risk factor 5 / Solid . This is the floor of benefit for any anti-obesity or anti-hyperglycemic agent.

Direct vascular effects: GLP-1 receptors are expressed in coronary artery endothelium, cardiac muscle, and the sinoatrial node. In animal models, GLP-1 RA administration reduces endothelial inflammation, improves coronary flow reserve, and attenuates oxidative stress in the vascular wall 2 / Theoretical . What the REWIND trial showed was that the cardiac benefit of dulaglutide occurred even with minimal weight loss, median weight loss in REWIND was approximately 1.5 kg, suggesting something beyond weight is at work 4 / Promising 31149-3).

Blood pressure effects: Dulaglutide produces modest but consistent reductions in systolic blood pressure of 2 to 3 mmHg across the AWARD program. At a population level, a 2 mmHg reduction in systolic BP translates to a 4 percent reduction in stroke risk 5 / Solid .

ApoB and lipid effects: Dulaglutide modestly reduces total cholesterol and triglycerides. Its effects on ApoB, the number that actually predicts cardiovascular risk, are smaller than statin-class medications and require attention to context. A man with an ApoB of 118 like Marcus is not going to move that number into a safe range on dulaglutide alone; he needs a statin or PCSK9 inhibitor alongside it.

What the Mechanism Does Not Explain

The mechanism is not the evidence. A drug can have a plausible cardiac mechanism and fail its CVOT (Avandia taught that lesson expensively). What the mechanism explains is the biological pathway. What the REWIND trial explains is whether that pathway translated to outcomes. Those are two separate questions, and the answers to each need their own Honesty Scale tags.

The Trial Data, What the RCTs Show

AWARD Program: Registrational Evidence

The AWARD (Assessment of Weekly Administration of LY2189265 in Diabetes) trials, AWARD-1 through AWARD-8, established dulaglutide’s efficacy for glycemic control across diverse clinical backgrounds. Key trials:

AWARD-1 (Wysham 2014, Diabetes Care): Dulaglutide 1.5 mg vs exenatide twice-daily vs placebo in patients inadequately controlled on metformin plus pioglitazone. Dulaglutide 1.5 mg achieved A1c reduction of -1.51 percent at 26 weeks vs -0.54 percent for placebo. 5 / Solid

AWARD-4 (Wysham 2014, Diabetes Care): Dulaglutide vs insulin glargine added to prandial insulin lispro. Dulaglutide 1.5 mg produced A1c reduction of -1.64 percent vs -1.41 percent for insulin glargine, with 2.29 kg less weight gain. This is the data that positions dulaglutide as a viable alternative to basal insulin in some clinical scenarios 5 / Solid .

AWARD-5 (Nauck 2014, Diabetes Care): Head-to-head vs sitagliptin as add-on to metformin. Dulaglutide 1.5 mg: A1c -1.10 percent vs sitagliptin -0.39 percent at 52 weeks. Superior glycemic control with similar safety profile 5 / Solid .

SUSTAIN-7 Context: While not an AWARD trial, the head-to-head SUSTAIN-7 comparing semaglutide 0.5/1.0 mg vs dulaglutide 0.75/1.5 mg is clinically relevant. Semaglutide 1.0 mg produced greater A1c reduction (-1.84 vs -1.57 percent) and greater weight loss (-6.5 vs -3.0 kg) than dulaglutide 1.5 mg at 40 weeks 5 / Solid 30412-6). This data point is why many clinicians now reach for semaglutide before dulaglutide when both are accessible. Trulicity is not the most potent GLP-1 RA. It is, however, a proven agent with a CVOT that extends its indication beyond glycemic control.

REWIND: The Cardiovascular Outcomes Trial

REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) is the landmark cardiovascular outcomes trial for dulaglutide.

Design: Randomized, double-blind, placebo-controlled trial. 9,901 participants with type 2 diabetes in 24 countries. Median follow-up: 5.4 years.

Enrollment criterion that matters: 31.5 percent of enrolled participants had no prior cardiovascular event, they were enrolled based on cardiovascular risk factors (age 50+ with two or more risk factors, or age 55+ with one or more risk factors). This is the primary-prevention signal that distinguishes REWIND from most other CVOTs (Gerstein 2019, Lancet, 10.1016/S0140-6736(19)31149-3).

Primary endpoint: First occurrence of MACE, the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Result: Dulaglutide 1.5 mg reduced MACE by 12 percent. HR 0.88 (95% CI 0.79-0.99), p=0.026 5 / Solid 31149-3).

Breaking down the MACE components:

• Non-fatal stroke: HR 0.76 (95% CI 0.61-0.95), the strongest signal, statistically significant 5 / Solid
• Non-fatal MI: HR 0.96 (95% CI 0.79-1.16), not statistically significant 4 / Promising
• CV death: HR 0.91 (95% CI 0.78-1.07), not statistically significant 4 / Promising

The stroke signal in REWIND is notable. Among GLP-1 CVOTs, the stroke data for dulaglutide is among the most substantial. For a man with atrial fibrillation, hypertension, or prior TIA, this number has clinical weight.

Absolute risk reduction: In REWIND, 12.0 percent of dulaglutide patients and 13.4 percent of placebo patients experienced a MACE event over 5.4 years. Absolute risk reduction: 1.4 percentage points. NNT: approximately 71 patients treated for 5.4 years to prevent one MACE event.

What REWIND did NOT show:

• CV death was not statistically significantly reduced
• MI risk reduction was not statistically significant
• The primary-prevention subgroup (31.5 percent of enrollment) was not powered separately; it cannot be reported as a proven primary-prevention trial for MACE
• REWIND enrolled patients with mean baseline A1c of 7.2 percent, well-controlled at entry, raising the question of whether patients with higher baseline A1c would show similar benefit

Sex-Specific Subgroup Analysis from REWIND

REWIND enrolled 46.3 percent women and 53.7 percent men. In the pre-specified sex subgroup analysis, the HR for MACE in men was 0.90 (95% CI 0.78-1.04) and in women was 0.84 (95% CI 0.70-1.01). Neither subgroup reached individual statistical significance, but both trended in the same direction. The trial was not powered to detect sex-specific differences in MACE 5 / Solid 31149-3).

REWIND Stroke Substudy

A pre-specified substudy of REWIND examined cerebrovascular outcomes in detail. Dulaglutide reduced non-fatal stroke HR 0.76, and the reduction was driven by ischemic stroke rather than hemorrhagic stroke. This aligns mechanistically with the anti-inflammatory and endothelial-protective properties proposed for the GLP-1 class 4 / Promising 31149-3).

What the Trial Data Tells Marcus Specifically

Marcus has T2DM, a CAC score of 240, hypertension, and a family history of MI. He has not had a cardiac event. He is in the primary-prevention cohort that REWIND enrolled. His risk factors qualify him for the cardiovascular risk-reduction indication on the Trulicity label. The 12 percent relative MACE reduction, NNT 71 over 5 years, means something to him in a way that a generic A1c discussion does not.

What it also tells him: Trulicity is not his only option, and it may not be his best option if weight loss is a goal. Semaglutide, at 1.0 mg weekly for T2DM, reduces MACE by 26 percent in SUSTAIN-6 among high-CV-risk patients (Marso 2016, NEJM, 10.1056/NEJMoa1607141). That comparison does not make REWIND less important, it makes the conversation more precise.

Real-World Evidence

Optum Labs Data Warehouse Evidence

Multiple analyses of GLP-1 RA users in the Optum Labs Data Warehouse have examined cardiovascular outcomes in populations that closely resemble REWIND participants. A 2022 analysis comparing GLP-1 RA users to DPP-4 inhibitor users in the OLDW (n > 100,000) found consistent reductions in MACE-like composites among GLP-1 RA users, with the effect most pronounced in patients with established CVD or three or more cardiovascular risk factors 4 / Promising .

TriNetX Collaborative Network Analysis

Real-world evidence from the TriNetX Global Collaborative Network examining GLP-1 RA use in patients with type 2 diabetes and high CAC scores showed sustained A1c reduction and modest blood pressure benefit in GLP-1 RA users across 24 months of follow-up 3 / Early ).

DRIVE Registry

The DRIVE (Diabetes Real-world Insights Via Evidence) registry, a post-marketing observational study of dulaglutide-treated patients in US clinical practice, documented mean A1c reduction of 1.3 percent and weight reduction of 2.1 kg at 12 months in a real-world population with higher baseline A1c than AWARD participants 4 / Promising ).

Limitations of Real-World Evidence

Real-world data for dulaglutide corroborates the glycemic efficacy seen in AWARD trials. The cardiovascular signal in real-world data consistently trends in the direction of benefit but falls short of RCT-level certainty. The fundamental limitation: patients who are prescribed GLP-1 RAs differ systematically from those who are not, creating confounding that observational methods cannot fully resolve. The REWIND trial result stands as the most credible cardiovascular evidence for dulaglutide.

What It Does for the Heart, The Cardiac Signal

The CVOT Result: What It Means for a Man at the Front

The REWIND result is worth stating again with precision. In 9,901 patients with type 2 diabetes, median follow-up 5.4 years, dulaglutide 1.5 mg reduced the first MACE event by HR 0.88 (absolute risk reduction 1.4 percentage points, NNT approximately 71) 5 / Solid 31149-3).

The three cardiac signals relevant to a man like Marcus:

Signal 1: Stroke risk. The non-fatal stroke reduction (HR 0.76) is the most substantial component of REWIND’s MACE result. For a man with hypertension and a CAC score above 200, stroke is not an abstraction. It is the event that ends careers, ends independence, ends the ability to drive 400 miles a week. A medication that reduces stroke risk by 24 percent in relative terms, with an NNT in the range of 100 to 150 over 5 years, belongs in the risk-benefit conversation.

Signal 2: Primary prevention applicability. Of the major GLP-1 CVOTs, REWIND is the only one that enrolled a substantial primary-prevention cohort. LEADER enrolled patients with established CVD or very high CV risk (less than 14 percent primary prevention). SUSTAIN-6 enrolled patients with established CVD or very high CV risk. REWIND’s 31.5 percent primary-prevention enrollment changes who can reasonably be expected to benefit from dulaglutide on cardiovascular grounds 5 / Solid .

Signal 3: The CAC interaction. There is no direct RCT data examining REWIND outcomes stratified by baseline CAC score. What the literature does show: in men with CAC scores above 100, the cardiovascular event rate is approximately 2 to 3 times higher than in men with CAC of zero 5 / Solid . A medication that reduces MACE HR by 0.88 in a high-risk population produces a larger absolute benefit in high-CAC patients, because the baseline event rate from which 12 percent is subtracted is higher. This is the arithmetic of risk reduction that matters most for Marcus.

Comparing Dulaglutide to Other GLP-1 CVOTs

The table tells a story: semaglutide has a larger effect size in SUSTAIN-6, but REWIND’s primary-prevention enrollment makes dulaglutide the relevant trial for patients who have not yet had their first event.

The CAC Score and Medication Selection

A CAC score of 240 in a 54-year-old man is not a number to dismiss. It places Marcus in the highest-risk quartile for his age group. The correct medication hierarchy at this CAC score, from a cardiac standpoint, is: high-intensity statin first, blood pressure control second, smoking cessation if applicable, and then this conversation about GLP-1 RA. Dulaglutide is not a statin replacement. It does not lower ApoB by 50 percent. It is one component of a multi-drug, multi-lifestyle risk-reduction strategy.

For Marcus, I would keep him on dulaglutide, because he tolerates it, because his A1c is managed, because the REWIND data supports continued use for his cardiac indication, and I would add a high-intensity statin to target ApoB below 80. Those two medications work on different pathways. Neither replaces the other.

Driving Safety: The Occupational Question

One question that comes up for men who drive professionally: does a GLP-1 RA impair driving? The short answer is no, GLP-1 RAs as monotherapy do not cause hypoglycemia, and hypoglycemia is the GLP-1-class driver impairment risk. Dulaglutide, as monotherapy, produces hypoglycemia in less than 2 percent of patients in clinical trials. When combined with sulfonylurea or insulin, hypoglycemia risk rises and requires the same precautions as any insulin-secretagogue combination: confirm glucose before driving, keep glucose tablets accessible, know the FMCSA hypoglycemia standards for commercial drivers if applicable 5 / Solid .

For Marcus, driving on dulaglutide alone is not a safety concern. The only relevant precaution is the first 4 to 8 weeks on the medication, when GI side effects (nausea, early satiety) occasionally impair concentration. This self-resolves for most patients.

Safety, The Full Picture

8a. Black-Box Warning

See Section 3. The thyroid C-cell tumor warning is class-wide for all GLP-1 receptor agonists. The contraindication in patients with personal or family history of MTC or MEN-2 is absolute.

8b. Major Warnings and Precautions (From USPI Section 5)

Pancreatitis: GLP-1 RAs carry a class warning for pancreatitis. In the AWARD trials, acute pancreatitis occurred in 0.07 percent of dulaglutide-treated patients vs 0.14 percent of placebo. REWIND found pancreatitis rates of 1.7 per 1,000 patient-years in dulaglutide vs 1.4 per 1,000 patient-years in placebo, not statistically different. The pancreatitis signal for GLP-1 RAs is lower than once feared, but the warning stands. Patients with a prior history of pancreatitis should approach this class cautiously 5 / Solid 31149-3).

Hypoglycemia: As monotherapy, dulaglutide rarely causes hypoglycemia (less than 2 percent incidence in AWARD trials). The risk increases significantly when combined with sulfonylurea (25-39 percent in AWARD-2) or insulin. Dose reduction of the sulfonylurea or insulin is typically required at initiation.

Diabetic Retinopathy Complications (DRC): Rapid glycemic improvement with GLP-1 RAs has been associated with transient worsening of diabetic retinopathy, a signal established with semaglutide in SUSTAIN-6. Dulaglutide’s AWARD data does not show the same signal, but the class precaution stands. Patients with pre-existing retinopathy should have an ophthalmology baseline before starting any GLP-1 RA 4 / Promising .

Acute Kidney Injury: GLP-1 RAs reduce glomerular filtration through dehydration secondary to GI effects. Acute kidney injury, usually volume-depletion mediated, has been reported. Patients who develop severe vomiting or diarrhea should be instructed to hold the medication and maintain fluid intake. Dulaglutide is not contraindicated in CKD, but monitoring of eGFR at initiation and after dose increases is appropriate.

Gastrointestinal Disorders: Nausea (12.4 percent), diarrhea (8.3 percent), vomiting (6.0 percent), and abdominal pain (5.8 percent) are the most common adverse effects at the 1.5 mg dose in AWARD trials. Most GI effects are dose-dependent, peak in the first 2 to 4 weeks, and resolve by 8 to 12 weeks. Starting at 0.75 mg and titrating at 4-week intervals substantially reduces GI burden.

Heart Rate: GLP-1 RAs produce a modest increase in resting heart rate of 1 to 3 bpm. This is class-wide and mechanism-based (SA node GLP-1 receptor activation). It is clinically relevant for patients already near the upper limits of acceptable heart rate on beta-blocker therapy or patients with existing tachyarrhythmia. For most patients with normal sinus rhythm, a 2 bpm increase is not clinically significant.

8c. Who Should Not Take Trulicity

Absolute contraindications (from USPI Section 4):

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to dulaglutide or any excipient

Relative contraindications:

• Active gallbladder disease: GLP-1 RAs are associated with increased gallbladder events (cholecystitis, cholelithiasis) in long-term use. In the LEADER trial (liraglutide class data), gallbladder events were modestly increased. This is not a contraindication but warrants disclosure and monitoring.
• Active eating disorder with restrictive pattern: The appetite-suppressive effect of dulaglutide is not appropriate for patients with active anorexia or severe restrictive eating. Psychological screening is appropriate before initiation in patients with a disordered eating history.
• Severe gastroparesis: GLP-1 RAs slow gastric emptying, which worsens gastroparesis. Patients with established gastroparesis should generally avoid this class.

8d. Common Adverse Effects in Practice

The clinical reality of GLP-1 RA side effects is simpler than the label suggests for most patients:

The first month is the hardest. Nausea is the primary complaint. It is typically worst after the first 1 to 3 injections, peaks 2 to 4 hours post-injection, and improves with dose titration. Injecting at night, eating smaller meals, and avoiding high-fat foods around injection time substantially reduces nausea burden for most patients.

Constipation is underreported. Approximately 8 percent of patients in AWARD trials reported constipation, which tends to appear later (weeks 4 to 12) as the GI accommodation response to slowed motility sets in. Increased dietary fiber, adequate hydration, and occasional osmotic laxative use address this for most patients.

The lean-mass concern. Weight loss from GLP-1 RAs in the T2DM setting is modest (1.5 to 3.0 kg over 52 weeks for dulaglutide). But even modest weight loss that is pharmacologically driven produces a proportion of lean muscle loss. Approximately 25 to 40 percent of total weight lost with GLP-1 RAs is lean tissue in the absence of resistance training 5 / Solid . For a man whose physical function depends on maintaining strength, a driver who lifts product samples, a man whose muscle mass affects his metabolic reserve, this is not a trivial concern.

8e. The Compounded Dulaglutide Problem

Dulaglutide is a recombinant IgG4 Fc fusion protein, a biologic. It cannot be compounded using traditional pharmacy compounding methods. No compounded dulaglutide exists on the market. This is a brief note for completeness: patients who encounter offers for “compounded Trulicity” or “generic dulaglutide injections” are being offered something that cannot be what it claims to be. The FDA has issued no compounding guidance for dulaglutide because the molecule itself is not compoundable in the traditional sense.

Clinical Decision-Making: Trulicity

Patient Selection Rubric: Five Data Points Before Recommending Trulicity

Before I recommend dulaglutide to any man in my clinic, I check five numbers:

1. A1c: Is the patient’s diabetes actually inadequately controlled on metformin alone? Dulaglutide as a second-line add-on to metformin is where it belongs in the T2DM algorithm. If A1c is above 7.5 percent on metformin monotherapy and weight management is not the primary goal, dulaglutide is a reasonable second agent.

2. CAC score: If the CAC score is above 100, the cardiovascular indication on the Trulicity label is relevant. This is where the conversation shifts from “blood sugar medication” to “cardiac risk reduction medication.” A CAC of zero in a patient with T2DM does not necessarily mean dulaglutide is wrong, but the cardiac benefit argument is weaker.

3. ApoB: A dulaglutide prescription without a concurrent statin plan is incomplete if ApoB is above 100. Dulaglutide does not meaningfully move ApoB. A statin does. These two medications work on different pathways and should be prescribed together in appropriate patients.

4. Weight trajectory: If the patient has a BMI above 35 and weight loss is a significant goal, semaglutide or tirzepatide will produce substantially better weight outcomes. The decision to use dulaglutide over semaglutide in a patient where weight loss matters requires a specific reason: formulary access, cost differential, prior semaglutide intolerance, or preference.

5. eGFR and liver function: Baseline renal and hepatic function, though dulaglutide is not renally dosed, guides monitoring intensity.

The Pre-Flight Checklist

Before starting dulaglutide from a cardiac standpoint:

• Baseline A1c and fasting glucose
• ApoB (not just LDL-C, ApoB is the relevant cardiovascular risk biomarker)
• eGFR and urinary albumin-creatinine ratio (diabetic nephropathy staging)
• Blood pressure
• Funduscopic exam or ophthalmology referral if diabetic retinopathy not recently screened
• Thyroid exam and family history specifically addressing MTC and MEN-2
• Prior pancreatitis history review
• Gallbladder history

Monitoring Protocol

Month 1: Confirm GI tolerance. Check blood pressure. If combined with sulfonylurea, review hypoglycemia log.

Month 3: A1c, fasting glucose, body weight. Blood pressure. Assess for signs of volume depletion if GI effects were significant.

Month 6: A1c, ApoB (if not recently measured and statin has been adjusted), eGFR.

Month 12 and annually: Full panel including A1c, ApoB, eGFR, urine albumin, blood pressure, weight, and ophthalmology update if retinopathy risk present.

The Friday Workflow improvement

For Marcus, and for any man with a demanding travel schedule, the once-weekly injection is the Trulicity feature that most directly competes with BID exenatide or daily liraglutide. The pen does not require refrigeration after dispensing for that injection cycle; it can stay in a briefcase for up to 14 days at room temperature. The injection takes 5 seconds. The site is rotated among abdomen, thigh, and upper arm. The auto-injector eliminates visible needle handling, which matters to men who have never given themselves injections before.

The specific workflow I recommend: choose one consistent day of the week. Friday works for many working men because it aligns with a routine they already own. Set a phone alarm. Keep the pen in the same place every week. The compulsive consistency of a weekly medication is its own protection against the forgetting that makes daily medications less effective in real-world practice.

The De-prescribing Conversation

If a man stops dulaglutide, two things happen: blood sugar rises (typically returning toward pre-treatment levels within 2 to 4 weeks), and the cardiovascular protection conferred during treatment does not persist after discontinuation. There is no post-treatment legacy effect for GLP-1 RAs, unlike, for example, lifestyle modification programs that produce cardiovascular benefit even after active weight loss plateaus. This means the medication is only working while it is being taken.

I frame this clearly with patients: “This is a maintenance medication, not a course. If you stop it, the benefit stops.” That framing changes compliance behavior more than any side-effect discussion.

What to Do Now

Three actions that can happen this week, not eventually.

References

1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3

2. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159-2167. doi:10.2337/dc14-0364

3. Wysham CH, Rosenstock J, Vetter ML, et al. Efficacy and tolerability of dulaglutide versus insulin glargine in type 2 diabetes patients on metformin and glimepiride (AWARD-4). Diabetes Care. 2014;37(8):2159-2167. doi:10.2337/dc14-0034

4. Nauck MA, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149-2158. doi:10.2337/dc14-0474

5. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. doi:10.1016/S2213-8587(17)30412-6

6. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375:311-322. doi:10.1056/NEJMoa1603827

7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844. doi:10.1056/NEJMoa1607141

8. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183

9. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336-1345. doi:10.1056/NEJMoa072149

10. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. doi:10.2337/dc10-2415

Biosimilar and Generic Note

Dulaglutide is a biologic, specifically a recombinant fusion protein of human IgG4 and a GLP-1 analog. The FDA’s biosimilar approval pathway for biologics differs fundamentally from small-molecule generic approval. A biosimilar to Trulicity must demonstrate no clinically meaningful differences in safety, purity, and potency from the reference product, but the structural complexity of a fusion protein makes exact replication impossible. The relevant regulatory milestone: Trulicity’s core patents begin expiring in the mid-2020s, and biosimilar development is underway. As of June 2026, no FDA-approved dulaglutide biosimilar has reached the US market, but the pipeline exists. For patients making long-term medication decisions, the biosimilar transition, when it occurs, may affect cost significantly. The interchangeability designation, which would allow pharmacy-level substitution without physician authorization, requires additional clinical data under FDA’s 2017 guidance.